Odefsey ([rilpivirine + emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Johnson & Johnson) Drug Overview 2019

Drug Overview
Odefsey ([rilpivirine + emtricitabine + tenofovir alafenamide (TAF)]; Gilead/Johnson & Johnson) is a single-tablet regimen approved in the US and five major EU markets (France, Germany, Italy, Spain, and the UK) for the treatment of HIV-1 infection. Odefsey contains Gilead’s nucleos(t)ide reverse transcriptase inhibitors (NRTIs) TAF and Emtriva (emtricitabine), and Johnson & Johnson's non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine; Johnson & Johnson).

Odefsey’s superior bone and renal safety profile has allowed it to cannibalize Complera’s ([rilpivirine + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead/Johnson & Johnson) patient share, but efficacy weaknesses associated with the Edurant component limit Odefsey’s potential outside of its current positioning as a more tolerable alternative to Atripla ([efavirenz + emtricitabine + TDF]; Gilead).